Interested in Bringing a Group to Café? Schedule a Group Visit

Future of Surgery: Pitch Competition

September 21, 2017

B. Braun supplies the global healthcare market with products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment, and surgery, as well as services for hospitals, general practitioners, and the homecare sector.

Join B. Braun and the German Accelerator Life Sciences for a Pitch Competition on the Future of Surgery on September 21, 2017, at Venture Café Cambridge.

Five (5) medical device start-ups will be selected to pitch a panel of experts. Prizes will be awarded to two teams:

  • The 1st Place prize is $2,000 in cash OR a mentoring day with senior executives at the B. Braun North America headquarters in Pennsylvania.

  • The 2nd Place prize includes a $1,000 cash prize.


To apply for the competition, please send a one-pager to The application deadline is September 13, 2017.



Meet the Judges

Caroll H. Neubauer
Caroll H. Neubauer

B. Braun

Eric J. Evans

Mass Medical Angels & Launchpad Ventures

Rui Zhang
Rui Zhang

Azia Capital Partners

Kevin Schimelfenig
Kevin Schimelfenig

McGeever & SalesForce4Hire

Babak Movassaghi
Babak Movassaghi

InfiniteMD & Recon Therapeutics

Book Special Office Hours with B. Braun


David E. Banko B. Braun

David E. Banko

Director, Health Economics and Outcomes Research,  B. Braun Medical
Mr. Banko is Director, Health Economics and Outcomes Research at B. Braun Medical Inc. located in Bethlehem, Pennsylvania.   He is responsible for identifying strategies to leverage health economics and outcomes studies across the breadth of  B. Braun’s portfolio resulting in the differentiation of their products in a highly competitive market.  Mr. Banko partners with all levels of the Organization to develop an optimized evidence generation plan ensuring widespread adoption of their innovative products upon commercialization.  Mr. Banko is leading B. Braun Medical Inc in preparing for the challenges and opportunities associated with the transition to a value oriented healthcare system in the United States.

Mr. Banko brings over 20-years of medical device, diagnostics and hospital finance experience to B. Braun Medical Inc.  Most recently, he spent 12 years working with two operating companies that were part of the Johnson & Johnson family of companies.  During his time with J&J, he successfully leveraged outcomes evidence to shape Medicare’s National medical coverage and reimbursement policies and developed programs to assist hospitals and physicians in securing market access from Medicare and other third-party payors for FDA approved emerging medical device technologies.

He has lead efforts in developing responses to payer’s Health Technology Assessments (HTAs) and in educating internal business partners on the implications of major policy shifts such as Medicare’s bundled payment initiatives, comparative (cost) effectiveness and gainsharing. Mr. Banko gained extensive experience in health care finance and reimbursement working with healthcare systems in Northeastern Pennsylvania.

He received a B.S. degree in Liberal Studies from the University of Scranton and an M.S. degree in Finance from King’s College.   Mr. Banko is a Certified Public Accountant, licensed in the State of Pennsylvania.


Robert C. Spiro, PhD

Sr. Vice President of Biologics, Development, Scientific & Clinical Affairs,  Aesculap Biologics (a B. Braun Company)
Dr. Spiro received his BSc from McGill University, Montreal, Canada and a Ph.D. in Immunology from the University of Massachusetts Medical School, Worcester, MA. His academic career included a Post-Doctoral fellowship and Assistant Professorship in the Department of Immunology at the Research Institute of Scripps Clinic, La Jolla, CA with research focused on cancer immunology and the extracellular matrix. His industry career spans several start-up companies including Telios Pharmaceuticals, Orquest Inc., Fibrogen Inc., ISTO Technologies and Carbylan Therapeutics.  He has been involved in the design and development of wound healing, orthopedic and spine drug, device and biologic-device combination products including the Healos® bone graft substitute, the DeNovo NT® Graft for cartilage repair, and the InQu® bone graft substitute. His work is documented in over 25 issued patents and over 40 peer-reviewed publications. Dr. Spiro currently serves as the Senior Vice President of Biologics, Development, Scientific and Clinical Affairs at Aesculap Biologics, LLC, Aesculap Implant Systems, and Aesculap Inc. in Center Valley, PA, all members of the B. Braun family of companies. The global Aesculap product and development portfolio incorporates over 150 years of experience in a wide range of general surgical, orthopedic, spine and regenerative technology areas, including the NOVOCART® line of cell-based regenerative products for the treatment of damaged articular cartilage and intervertebral discs.

In collaboration with:

German Accelerator

Social Share Buttons and Icons powered by Ultimatelysocial